Skip to main content

Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.

Clinical Trials

BRCC Research Institute 2026

< All Clinical Trials

Tucatinib in Combination w/Doxil for HER2+ metastatic breast cancer

Disease Type: Breast

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Locations

Alleghany , Blacksburg , Roanoke , Salem , Wytheville

View on ClinicalTrials.gov